SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
75.97 USD   +0.30%
10:43aRoche, Sarepta Therapeutics' Muscular Disorder Drug Shows Benefit in Clinical Studies
MT
08:15aSarepta Therapeutics' Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
AQ
07/05SAREPTA THERAPEUTICS TO SHARE NEW CLINICAL DATA AND INTEGRATED ANALYSIS FOR SRP-9001, ITS INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF DUCHENNE M : 30am ET
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
77.07(c) 74.96(c) 75.71(c) 75.74(c) 75.97 Last
739 858 743 209 884 857 1 287 879 2 522 699 Volume
+3.21% -2.74% +1.00% +0.04% +0.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 900 M - -
Net income 2022 -375 M - -
Net cash position 2022 763 M - -
P/E ratio 2022 -17,1x
Yield 2022 -
Sales 2023 1 059 M - -
Net income 2023 -260 M - -
Net cash position 2023 523 M - -
P/E ratio 2023 -24,7x
Yield 2023 -
Capitalization 6 627 M 6 627 M -
EV / Sales 2022 6,52x
EV / Sales 2023 5,76x
Nbr of Employees 840
Free-Float 95,7%
More Financials
Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy... 
More about the company
Ratings of Sarepta Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SAREPTA THERAPEUTICS, INC.
10:43aRoche, Sarepta Therapeutics' Muscular Disorder Drug Shows Benefit in Clinical Studies
MT
08:15aSarepta Therapeutics' Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystr..
AQ
07/05SAREPTA THERAPEUTICS TO SHARE NEW CL : 30am ET
AQ
06/30Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
06/24Cantor Fitzgerald Adjusts Sarepta Therapeutics' Price Target to $128 from $140, Keeps O..
MT
06/24Credit Suisse Lowers Sarepta Therapeutics' Price Target to $90 from $95 After Muscular ..
MT
06/23Sarepta Therapeutics' Muscular Dystrophy Drug Study Put on FDA Hold; Stock Falls in Lat..
MT
06/23TRANSCRIPT : Sarepta Therapeutics, Inc. - Special Call
CI
06/23Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular..
AQ
06/23Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Mu..
CI
06/23Sarepta Says FDA Put Clinical Hold on Duchenne MD Drug, Shares Fall 8%
DJ
06/14TRANSCRIPT : Sarepta Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healt..
CI
06/03SAREPTA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matt..
AQ
06/02Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of..
AQ
06/02Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of D..
CI
More news
News in other languages on SAREPTA THERAPEUTICS, INC.
10:43aLe médicament contre les troubles musculaires de Roche et Sarepta Therapeutics présente..
06/23L'étude sur le médicament contre la dystrophie musculaire de Sarepta Therapeutics est m..
06/23Sarepta Therapeutics, Inc. fait le point sur le SRP-5051 pour le traitement de la dystr..
06/02Sarepta Therapeutics, Inc. nomme Michael Chambers et Kathryn Boor à son conseil d'admin..
05/04Earnings Flash (SRPT) SAREPTA THERAPEUTICS annonce un chiffre d'affaires de 210,8 milli..
More news
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
More recommendations
Chart SAREPTA THERAPEUTICS, INC.
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 75,74 $
Average target price 117,25 $
Spread / Average Target 54,8%
EPS Revisions
Managers and Directors
Douglas S. Ingram President, Chief Executive Officer & Director
Ian M. Estepan Executive VP, Chief Financial & Accounting Officer
M. Kathleen Behrens Wilsey Chairman
Louise Rodino-Klapac Chief Scientific Officer & Executive VP
Hans Lennart Rudolf Wigzell Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SAREPTA THERAPEUTICS, INC.-15.89%6 627
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.67%49 127
BIONTECH SE-37.54%39 133